Xigadap M 10/500 Tablet ER

Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose production, contributing to better glycemic control. The extended-release formulation ensures a gradual release of metformin, enhancing gastrointestinal tolerability and improving patient compliance. Xigadap M 10/500 Tablet ER is typically administered once daily with meals to minimize gastrointestinal side effects.

It is essential to monitor renal function prior to and during treatment, as both components are renally excreted. Common adverse effects may include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and rare cases of lactic acidosis. This medication should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia.

Xigadap M 10/500 Tablet ER offers an effective dual mechanism approach for improved glycemic control in type 2 diabetes management.